504 related articles for article (PubMed ID: 34759261)
1. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein.
Li H; Zhang Y; Li D; Deng YQ; Xu H; Zhao C; Liu J; Wen D; Zhao J; Li Y; Wu Y; Liu S; Liu J; Hao J; Yuan F; Duo S; Qin CF; Zheng A
Signal Transduct Target Ther; 2021 Nov; 6(1):389. PubMed ID: 34759261
[TBL] [Abstract][Full Text] [Related]
2. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
Kim GN; Choi JA; Wu K; Saeedian N; Yang E; Park H; Woo SJ; Lim G; Kim SG; Eo SK; Jeong HW; Kim T; Chang JH; Seo SH; Kim NH; Choi E; Choo S; Lee S; Winterborn A; Li Y; Parham K; Donovan JM; Fenton B; Dikeakos JD; Dekaban GA; Haeryfar SMM; Troyer RM; Arts EJ; Barr SD; Song M; Kang CY
PLoS Pathog; 2021 Dec; 17(12):e1010092. PubMed ID: 34914812
[TBL] [Abstract][Full Text] [Related]
3. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
[TBL] [Abstract][Full Text] [Related]
4. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
5. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
6. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.
Lu M; Chamblee M; Zhang Y; Ye C; Dravid P; Park JG; Mahesh KC; Trivedi S; Murthy S; Sharma H; Cassady C; Chaiwatpongsakorn S; Liang X; Yount JS; Boyaka PN; Peeples ME; Martinez-Sobrido L; Kapoor A; Li J
Proc Natl Acad Sci U S A; 2022 Aug; 119(35):e2110105119. PubMed ID: 35994646
[TBL] [Abstract][Full Text] [Related]
9. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19.
Xu K; An Y; Li Q; Huang W; Han Y; Zheng T; Fang F; Liu H; Liu C; Gao P; Xu S; Liu X; Zhang R; Zhao X; Liu WJ; Bi Y; Wang Y; Zhou D; Wang Q; Hou W; Xia Q; Gao GF; Dai L
Emerg Microbes Infect; 2021 Dec; 10(1):1574-1588. PubMed ID: 34289779
[TBL] [Abstract][Full Text] [Related]
10. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
[TBL] [Abstract][Full Text] [Related]
11. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
[TBL] [Abstract][Full Text] [Related]
14. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
15. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
16. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
17. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
Dulin H; Barre RS; Xu D; Neal A; Vizcarra E; Chavez J; Ulu A; Yang M-S; Khan SR; Wuang K; Bhakta N; Chea C; Wilson EH; Martinez-Sobrido L; Hai R
J Virol; 2024 Feb; 98(2):e0157123. PubMed ID: 38206036
[TBL] [Abstract][Full Text] [Related]
18. A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters.
Liu X; Luongo C; Matsuoka Y; Park HS; Santos C; Yang L; Moore IN; Afroz S; Johnson RF; Lafont BAP; Martens C; Best SM; Munster VJ; Hollý J; Yewdell JW; Le Nouën C; Munir S; Buchholz UJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34876520
[TBL] [Abstract][Full Text] [Related]
19. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
Srivastava V; Niu L; Phadke KS; Bellaire BH; Cho MW
Front Immunol; 2021; 12():637982. PubMed ID: 33777030
[TBL] [Abstract][Full Text] [Related]
20. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.
Li M; Guo J; Lu S; Zhou R; Shi H; Shi X; Cheng L; Liang Q; Liu H; Wang P; Wang N; Wang Y; Fu L; Xing M; Wang R; Ju B; Liu L; Lau SY; Jia W; Tong X; Yuan L; Guo Y; Qi H; Zhang Q; Huang Z; Chen H; Zhang Z; Chen Z; Peng X; Zhou D; Zhang L
Front Immunol; 2021; 12():697074. PubMed ID: 34262569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
